vs

Side-by-side financial comparison of Invesco (IVZ) and Roper Technologies (ROP). Click either name above to swap in a different company.

Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.7B, roughly 1.2× Invesco). Roper Technologies runs the higher net margin — 15.8% vs -58.9%, a 74.7% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 6.2%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $432.2M). Over the past eight quarters, Roper Technologies's revenue compounded faster (10.5% CAGR vs 7.1%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

IVZ vs ROP — Head-to-Head

Bigger by revenue
ROP
ROP
1.2× larger
ROP
$2.1B
$1.7B
IVZ
Growing faster (revenue YoY)
ROP
ROP
+5.1% gap
ROP
11.3%
6.2%
IVZ
Higher net margin
ROP
ROP
74.7% more per $
ROP
15.8%
-58.9%
IVZ
More free cash flow
ROP
ROP
$74.8M more FCF
ROP
$507.0M
$432.2M
IVZ
Faster 2-yr revenue CAGR
ROP
ROP
Annualised
ROP
10.5%
7.1%
IVZ

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IVZ
IVZ
ROP
ROP
Revenue
$1.7B
$2.1B
Net Profit
$-995.9M
$331.0M
Gross Margin
69.4%
Operating Margin
-86.2%
27.2%
Net Margin
-58.9%
15.8%
Revenue YoY
6.2%
11.3%
Net Profit YoY
-575.8%
53.7%
EPS (diluted)
$-2.61
$4.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
ROP
ROP
Q1 26
$2.1B
Q4 25
$1.7B
$2.1B
Q3 25
$1.6B
$2.0B
Q2 25
$1.5B
$1.9B
Q1 25
$1.5B
$1.9B
Q4 24
$1.6B
$1.9B
Q3 24
$1.5B
$1.8B
Q2 24
$1.5B
$1.7B
Net Profit
IVZ
IVZ
ROP
ROP
Q1 26
$331.0M
Q4 25
$-995.9M
$428.4M
Q3 25
$356.4M
$398.5M
Q2 25
$197.4M
$378.3M
Q1 25
$171.1M
$331.1M
Q4 24
$209.3M
$462.3M
Q3 24
$55.0M
$367.9M
Q2 24
$132.2M
$337.1M
Gross Margin
IVZ
IVZ
ROP
ROP
Q1 26
69.4%
Q4 25
69.5%
Q3 25
69.5%
Q2 25
69.2%
Q1 25
68.7%
Q4 24
68.3%
Q3 24
69.2%
Q2 24
69.5%
Operating Margin
IVZ
IVZ
ROP
ROP
Q1 26
27.2%
Q4 25
-86.2%
28.6%
Q3 25
16.5%
28.4%
Q2 25
14.1%
28.2%
Q1 25
18.1%
27.9%
Q4 24
19.6%
28.0%
Q3 24
6.6%
28.1%
Q2 24
13.9%
28.8%
Net Margin
IVZ
IVZ
ROP
ROP
Q1 26
15.8%
Q4 25
-58.9%
20.8%
Q3 25
21.7%
19.8%
Q2 25
13.0%
19.5%
Q1 25
11.2%
17.6%
Q4 24
13.1%
24.6%
Q3 24
3.6%
20.8%
Q2 24
8.9%
19.6%
EPS (diluted)
IVZ
IVZ
ROP
ROP
Q1 26
$4.87
Q4 25
$-2.61
$3.97
Q3 25
$0.66
$3.68
Q2 25
$-0.03
$3.49
Q1 25
$0.38
$3.06
Q4 24
$0.46
$4.29
Q3 24
$0.12
$3.40
Q2 24
$0.29
$3.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
ROP
ROP
Cash + ST InvestmentsLiquidity on hand
$1.0B
$382.9M
Total DebtLower is stronger
$1.8B
$9.7B
Stockholders' EquityBook value
$12.2B
$18.8B
Total Assets
$27.1B
$34.6B
Debt / EquityLower = less leverage
0.15×
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
ROP
ROP
Q1 26
$382.9M
Q4 25
$1.0B
$297.4M
Q3 25
$973.1M
$320.0M
Q2 25
$922.7M
$242.4M
Q1 25
$821.7M
$372.8M
Q4 24
$986.5M
$188.2M
Q3 24
$1.0B
$269.6M
Q2 24
$878.5M
$251.5M
Total Debt
IVZ
IVZ
ROP
ROP
Q1 26
$9.7B
Q4 25
$1.8B
$9.3B
Q3 25
$1.6B
Q2 25
$1.9B
Q1 25
$964.8M
Q4 24
$890.6M
$7.6B
Q3 24
$890.3M
Q2 24
$890.1M
Stockholders' Equity
IVZ
IVZ
ROP
ROP
Q1 26
$18.8B
Q4 25
$12.2B
$19.9B
Q3 25
$14.0B
$20.0B
Q2 25
$13.9B
$19.6B
Q1 25
$14.7B
$19.2B
Q4 24
$14.6B
$18.9B
Q3 24
$14.8B
$18.5B
Q2 24
$14.6B
$18.1B
Total Assets
IVZ
IVZ
ROP
ROP
Q1 26
$34.6B
Q4 25
$27.1B
$34.6B
Q3 25
$28.4B
$34.6B
Q2 25
$28.5B
$33.2B
Q1 25
$28.1B
$31.4B
Q4 24
$27.0B
$31.3B
Q3 24
$27.5B
$31.6B
Q2 24
$27.2B
$29.8B
Debt / Equity
IVZ
IVZ
ROP
ROP
Q1 26
0.52×
Q4 25
0.15×
0.47×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.07×
Q4 24
0.06×
0.40×
Q3 24
0.06×
Q2 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
ROP
ROP
Operating Cash FlowLast quarter
$455.8M
Free Cash FlowOCF − Capex
$432.2M
$507.0M
FCF MarginFCF / Revenue
25.5%
24.2%
Capex IntensityCapex / Revenue
1.4%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
ROP
ROP
Q1 26
Q4 25
$455.8M
$738.0M
Q3 25
$606.2M
$869.5M
Q2 25
$547.9M
$404.1M
Q1 25
$-84.6M
$528.7M
Q4 24
$316.9M
$722.2M
Q3 24
$438.4M
$755.4M
Q2 24
$489.1M
$384.1M
Free Cash Flow
IVZ
IVZ
ROP
ROP
Q1 26
$507.0M
Q4 25
$432.2M
Q3 25
$586.4M
Q2 25
$530.4M
Q1 25
$-108.0M
Q4 24
$309.9M
Q3 24
$410.0M
Q2 24
$462.4M
FCF Margin
IVZ
IVZ
ROP
ROP
Q1 26
24.2%
Q4 25
25.5%
Q3 25
35.7%
Q2 25
35.0%
Q1 25
-7.1%
Q4 24
19.5%
Q3 24
27.1%
Q2 24
31.2%
Capex Intensity
IVZ
IVZ
ROP
ROP
Q1 26
0.5%
Q4 25
1.4%
Q3 25
1.2%
Q2 25
1.2%
Q1 25
1.5%
Q4 24
0.4%
Q3 24
1.9%
Q2 24
1.8%
Cash Conversion
IVZ
IVZ
ROP
ROP
Q1 26
Q4 25
1.72×
Q3 25
1.70×
2.18×
Q2 25
2.78×
1.07×
Q1 25
-0.49×
1.60×
Q4 24
1.51×
1.56×
Q3 24
7.97×
2.05×
Q2 24
3.70×
1.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

ROP
ROP

Segment breakdown not available.

Related Comparisons